DCGI approves biological E’s Covid-19 vaccine ‘Corbevax’, vaccination of 12-15 age group will start soon

0
Corbevax vaccine

New Delhi: The Drugs Controller General of India (DCGI) (DCGI) on Monday announced emergency use of Biological E’s COVID-19 vaccine ‘Corbevax’ for children aged 12-18 years in India. has approved. It is to be known that till now in the country from January 3, 15-18-year-olds were being administered Covaxin of Bharat Biotech. However, the government has not yet taken any decision on vaccinating those below 15 years of age.

DCGI has given its approval on 28 December 2019 to Corbevax for emergency use on a limited basis for adults. This is an RBD-based vaccine developed in India against Covid-19.

‘Corbevax’ has become the third vaccine to gain approval from DCGI for the age group of 12 to 18 years. Earlier, Zydus Cadila’s Zycov-D and Bharat Biotech’s Covaccine were approved.

“BE received approval for restricted use in emergency situations in adolescents aged 12 to 18 years, based on interim results (ongoing Phase II/III clinical studies),” Biologicals said in a statement today. Corbevax is being billed as India’s first domestic “receptor-binding domain protein sub-unit vaccine” against COVID-19. The receptor-binding domain located on its “spike” domain is an important part of the virus that allows it to dock to the body’s receptors to enter and infect cells. These are also primary goals in the prevention and treatment of viral infections.

Biologicals e Managing Director Mahima Datla said in a statement, “We are delighted with this significant development, which helps increase the reach of our vaccines to the age group of 12 to 18 years in our country. We truly believe that with this approval, we are even closer to ending our global fight against it.”

Significantly, in September last year, the company got permission for the Phase II-III clinical trial of Corbevax on the age group of 5 to 18 years.

Corbevax vaccine

Biologicals said in its statement, “Based on the no-objection certificate, BE commenced clinical studies in October 2021 and evaluated the available safety and immunogenicity results of the ongoing Phase II/III study, which indicated Given that the vaccine is safe and immunogenic.”

The company said that the Corbevax vaccine will be delivered into the body via muscle and will have to be taken in two doses within 28 days. The vaccine is stored at 2 to 8 °C. It comes in 0.5 ml (single dose), 5 ml (10 dose) and 10 ml (20 dose) vial packs.

Advertisement